Clinical trials: Grippe
Seasonal Influenza
Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers
The present study will evaluate the safety in healthy people aged 1- 45 years (male and female) after single intramuscular (IM) dose of trivalent subunit inactivated influenza vaccine till the 30-days follow-up period.
- Trial name
- NCT01123954
- Testing
- Seasonal flu vaccine
- Where
- Vietnam
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.
This is a specimen collection protocol designed with the purpose of understanding the immune responses to influenza in children and adult subjects through collection of blood specimens and influenza medical history data.
- Trial name
- NCT01262079
- Where
- 4 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pre-pandemic Influenza Vaccine
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules
The present study will evaluate the immunogenicity, safety and immunogenicity of two doses of monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic…
- Trial name
- NCT00848029
- Testing
- Monovalent inactivated influenza vaccine
- Where
- Czechia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Swine-origin A/H1N1 Influenza
A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults
This study is designed to describe the immunogenicity of a pandemic A/H1N1 influenza vaccine in healthy adults given a lower vaccine dose and in a similar group given a full dose of the vaccine.
- Trial name
- NCT01089660
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated)
- Where
- 2 sites in France
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A
Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population
Adopt the design of random, blind method and placebo to parallel control and progressive methods of groups to study and evaluate the safety and immunogenicity of influenza A (H7N9) vaccine (two types, one type with two…
- Trial name
- NCT03196661
- Testing
- Influenza A (H7N9) virus vaccine
- Volunteers
- 588 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Bacterin Co. Ltd.
Influenza
The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study
This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine…
- Trial name
- DRIVE III (NCT07240922)
- Testing
- Live attenuated influenza vaccine, recombinant hemagglutinin influenza vaccine
- Where
- Hong Kong
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
The purpose of the study is to identify the optimal dose level of a reverse genetic (RG) reassortant H9N2 pandemic influenza vaccine for further product development.
- Trial name
- NCT01320696
- Testing
- Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
MAJOR DEPRESSIVE DISORDER
Influenza Challenge in Mood Disorders
The aim of this project is to evaluate the efficacy of the influenza vaccine in individuals with major depressive disorder (MDD) as well as to elucidate the nature of the immunological abnormalities in MDD using a…
- Trial name
- NCT02415166
- Testing
- INFLUENZA VACCINE
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Laureate Institute for Brain Research, Inc.
Seasonal Influenza
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy children aged 6-35 months.
- Trial name
- NCT03859141
- Testing
- Quadrivalent influenza vaccine, Trivalent influenza vaccine (contains B/Victoria strain), Trivalent influenza vaccine (contains B/Yamagata strain)
- Where
- 2 sites in China
- Volunteers
- 2,340 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Vaccination Reaction
Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine
The effect of LiteVax Adjuvant supplemented to licensed seasonal influenza vaccine on safety and immunogenicity will be investigated in both younger and older healthy participants.
- Trial name
- TETRALITE-Ib (NCT06294262)
- Testing
- TETRALITE
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- LiteVax BV
Healthy
Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean Volunteer
The purpose of this study to evaluate the safety of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) in comparison with Fluarix Prefilled Syringe (inactivated split influenza vaccine) after…
- Trial name
- NCT02330003
- Testing
- IL-YANG FLU Vaccine Prefilled Syringe INJ., Fluarix Prefilled Syringe
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 2 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407 compared to an…
- Trial name
- NCT05553301
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Swine-Origin Influenza A H1N1 Virus
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects
This study is to identify the preferred vaccine dosage (of antigen and adjuvant) and schedule (one or two administrations) of the cell-derived H1N1sw monovalent vaccine in healthy children/adolescents based on European Medicines…
- Trial name
- NCT01000207
- Testing
- Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
- Where
- Japan
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
Background: Influenza (flu) is a virus that infects people of all ages. Some people may have mild flu symptoms. Others may get very sick and even die from the flu.
- Trial name
- NCT05027932
- Testing
- BPL-1357
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Primary Objective: To demonstrate that high-dose quadrivalent influenza vaccine (QIV-HD) induces an immune response that is superior to the responses induced by standard-dose quadrivalent influenza vaccine (QIV-SD) for all 4…
- Trial name
- NCT04024228
- Testing
- Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD), High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 1,539 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 65 years and over
- Trial name
- NCT00522236
- Testing
- Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008
- Where
- 2 sites in Italy
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
The purpose of this study is to see how much antibody (proteins produced by the immune system that help fight infections) the body makes after getting a flu vaccine.
- Trial name
- NCT01173211
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children
The purpose of this study is to determine the efficacy of CAIV-T in a diverse Asian population aged from 6 months to less than 36 months, in tropical and temperate climates, against culture-confirmed influenza illness.
- Trial name
- NCT00192244
- Testing
- CAIV-T, Liquid
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants
The aim of this study is to investigate the immunogenicity and safety of the inactivated split-virion vaccine in infants.
- Trial name
- NCT01494740
- Testing
- split-virion, non-adjuvanted vaccine of 7.5 μg, split-virion, non-adjuvanted H1N1 vaccine of 15 μg, split-virion, non-adjuvanted vaccine of seasonal influenza
- Where
- China
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza, SARS-CoV-2
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to <65…
- Trial name
- NCT06508320
- Testing
- mRNA-1083
- Where
- 17 sites in United States, Canada
- Volunteers
- 931 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.